ArticleJournal of cellular physiology2026
Sexually Dimorphic Regulation of MiR-29a/c-3p in Human Endothelial Cells: Cell Functions and Transcriptome.
Article in Journal of cellular physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Preeclampsia (PE) is a major cause of maternal and fetal morbidity and mortality during pregnancy. PE is characterized by widespread endothelial dysfunction in mothers and fetuses. The etiology of PE remains elusive, but the dysregulation of microRNAs (miRNAs) in endothelial cells may contribute to the pathogenesis of PE. We have reported that PE downregulates expression of two miRNAs, miR-29a-3p and miR-29c-3p (miR-29a/c-3p), and knockdown of miR-29a/c-3p impairs functions of human umbilical vein endothelial cells (HUVECs). Herein, we tested the hypothesis that knockdown of miR-29a/c-3p sex-specifically impairs cellular responses to vascular endothelial growth factor-A (VEGFA) and fibroblast growth factor 2 (FGF2) via disrupting the transcriptome in HUVECs. MiR-29a/c-3p were knocked down using miR-29c-3p inhibitors in male and female HUVECs. Chemotactic and proliferative responses to VEGFA and FGF2 were assessed. RNA-seq was performed to identify miR-29a/c-3p regulated genes and pathways. Knockdown analysis demonstrated that miR-29c-3p inhibitors decreased miR-29a/c-3p levels by over 95% in male and female HUVECs. Functionally, miR-29c-3p inhibitors suppressed VEGFA-, but not FGF2-stimulated chemotaxis by 26% in male, but not female HUVECs. RNA-seq revealed that miR-29a/c-3p inhibitors dysregulated 47 and 118 genes in male and female HUVECs, respectively. Bioinformatics analyses showed that miR-29a/c-3p-regulated genes were differently associated with hypertension, heart, angiogenesis, and immunology in male and female HUVECs. These data demonstrate that knockdown of miR-29a/c-3p sex-specifically affects cellular responses to VEGFA and FGF2 in HUVECs, possibly via disrupting the transcriptome and relevant pathways. These miR-29a/c-3p-regulated genes might represent promising sex-specific therapeutic targets for PE-associated endothelial dysfunction pending further in vivo and clinical verification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.